MetLife Investment Advisors LLC bought a new stake in Guardant Health Inc (NASDAQ:GH) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 8,622 shares of the company’s stock, valued at approximately $324,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Guardant Health during the 4th quarter valued at approximately $26,000. Citigroup Inc. acquired a new stake in shares of Guardant Health during the 4th quarter valued at approximately $94,000. Victory Capital Management Inc. acquired a new stake in shares of Guardant Health during the 4th quarter valued at approximately $124,000. Pendal Group Ltd acquired a new stake in shares of Guardant Health during the 4th quarter valued at approximately $213,000. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Guardant Health during the 4th quarter valued at approximately $220,000. 69.45% of the stock is currently owned by institutional investors.
GH has been the topic of several research reports. Bank of America reissued a “neutral” rating and set a $60.00 price target (up from $42.00) on shares of Guardant Health in a research report on Thursday, February 28th. JPMorgan Chase & Co. upped their price target on Guardant Health from $42.00 to $85.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. William Blair reissued an “outperform” rating on shares of Guardant Health in a research report on Wednesday, March 13th. Zacks Investment Research lowered Guardant Health from a “hold” rating to a “sell” rating in a research report on Monday, March 18th. Finally, Cowen upped their price target on Guardant Health from $40.00 to $70.00 and gave the company an “outperform” rating in a research report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Guardant Health has an average rating of “Buy” and an average price target of $79.67.
Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Tuesday, March 12th. The company reported ($0.30) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.05. The company had revenue of $32.87 million for the quarter, compared to the consensus estimate of $24.57 million. On average, analysts anticipate that Guardant Health Inc will post -1.5 earnings per share for the current year.
In related news, major shareholder Vision Fund (Aiv M1) Softbank acquired 2,033,990 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was purchased at an average cost of $9.83 per share, for a total transaction of $19,994,121.70. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4296203/metlife-investment-advisors-llc-invests-324000-in-guardant-health-inc-gh.html.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health Inc (NASDAQ:GH).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.